FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:1584-1586 May 16, 2002 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article Related Article by Casadevall, N. PubMed Citation

To the Editor: Casadevall et al. (Feb. 14 issue)¹ reported 13 cases of pure red-cell aplasia and antierythropoietin antibodies in European patients who received recombinant erythropoietin (epoetin). Data submitted to the Food and Drug Administration suggest important differences among brands of epoetin with regard to recent increases in reports of pure red-cell aplasia.

Epogen, Procrit, and Eprex are brands of epoetin licensed in the United States. Epogen and Procrit are identical formulations of the same active ingredient (epoetin) distributed only in the United States. Eprex is a different product, which is distributed only outside the United States. For all biologic . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Macdougall, I. C., Rossert, J., Casadevall, N., Stead, R. B., Duliege, A.-M., Froissart, M., Eckardt, K.-U. (2009). A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia. NEJM 361: 1848-1855 [Abstract] [Full Text]  
• Schellekens, H. (2009). Biosimilar therapeutics--what do we need to consider?. NDT Plus 2: i27-i36 [Abstract] [Full Text]  
• Locatelli, F., Del Vecchio, L., Pozzoni, P. (2007). PURE RED-CELL APLASIA "EPIDEMIC"--MYSTERY COMPLETELY REVEALED?. pdi 27: S303-S307 [Abstract] [Full Text]  
• Sloand, E. M., Scheinberg, P., Maciejewski, J., Young, N. S. (2006). Brief Communication: Successful Treatment of Pure Red-Cell Aplasia with an Anti-Interleukin-2 Receptor Antibody (Daclizumab). ANN INTERN MED 144: 181-185 [Abstract] [Full Text]  
• Henson, S. M., Snelgrove, R., Hussell, T., Wells, D. J., Aspinall, R. (2005). An IL-7 Fusion Protein That Shows Increased Thymopoietic Ability. J. Immunol. 175: 4112-4118 [Abstract] [Full Text]  
• Tangri, S., Mothe, B. R., Eisenbraun, J., Sidney, J., Southwood, S., Briggs, K., Zinckgraf, J., Bilsel, P., Newman, M., Chesnut, R., LiCalsi, C., Sette, A. (2005). Rationally Engineered Therapeutic Proteins with Reduced Immunogenicity. J. Immunol. 174: 3187-3196 [Abstract] [Full Text]  
• Thorpe, R., Swanson, S. J (2005). Current Methods for Detecting Antibodies against Erythropoietin and Other Recombinant Proteins. CVI 12: 28-39 [Full Text]  
• Cournoyer, D., Toffelmire, E. B., Wells, G. A., Barber, D. L., Barrett, B. J., Delage, R., Forrest, D. L., Gagnon, R. F., Harvey, E. A., Laneuville, P., Patterson, B. J., Poon, M.-C., Posen, G. A., Messner, H. A., the members of the Canadian PRCA Focus Group, (2004). Anti-Erythropoietin Antibody-Mediated Pure Red Cell Aplasia after Treatment with Recombinant Erythropoietin Products: Recommendations for Minimization of Risk. J. Am. Soc. Nephrol. 15: 2728-2734 [Abstract] [Full Text]  
• Bennett, C. L., Luminari, S., Nissenson, A. R., Tallman, M. S., Klinge, S. A., McWilliams, N., McKoy, J. M., Kim, B., Lyons, E. A., Trifilio, S. M., Raisch, D. W., Evens, A. M., Kuzel, T. M., Schumock, G. T., Belknap, S. M., Locatelli, F., Rossert, J., Casadevall, N. (2004). Pure Red-Cell Aplasia and Epoetin Therapy. NEJM 351: 1403-1408 [Abstract] [Full Text]  
• Vartia, A., Asola, M. R., Tertti, R., Kunelius, P., Metsarinne, K. P. (2004). Two haemodialysis patients with epoetin alfa-induced pure red-cell aplasia recovered despite treatment with another epoetin preparation. Nephrol Dial Transplant 19: 1313-1316 [Full Text]  
• Locatelli, F., Aljama, P., Barany, P., Canaud, B., Carrera, F., Eckardt, K.-U., Macdougall, I. C., Macleod, A., Horl, W. H., Wiecek, A., Cameron, S. (2004). Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here?. Nephrol Dial Transplant 19: 288-293 [Full Text]  
• Navarro, J. F. (2003). In the erythropoietin era, can we forget alternative or adjunctive therapies for renal anaemia management? The androgen example. Nephrol Dial Transplant 18: 2222-2226 [Full Text]  
• Ng, T, Marx, G, Littlewood, T, Macdougall, I (2003). Recombinant erythropoietin in clinical practice. Postgrad. Med. J. 79: 367-376 [Abstract] [Full Text]  
• Eckardt, K.-U., Casadevall, N. (2003). Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant 18: 865-869 [Full Text]  
• Bagshaw, S. M., Ghali, W. A. (2003). Erythropoietin and Transfusions Among Critically Ill Patients. JAMA 289: 1511-1511 [Full Text]  
• Weber, G., Gross, J., Kromminga, A., Loew, H.-H., Eckardt, K.-U. (2002). Allergic Skin and Systemic Reactions in a Patient with Pure Red Cell Aplasia and Anti-Erythropoietin Antibodies Challenged with Different Epoetins. J. Am. Soc. Nephrol. 13: 2381-2383 [Abstract] [Full Text]